I
Indrajeet Singh
Researcher at Johnson & Johnson
Publications - 1
Citations - 57
Indrajeet Singh is an academic researcher from Johnson & Johnson. The author has contributed to research in topics: Myeloid leukemia & Decitabine. The author has an hindex of 1, co-authored 1 publications receiving 24 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Pau Montesinos,Gail J. Roboz,Claude Eric Bulabois,Marion Subklewe,Uwe Platzbecker,Yishai Ofran,Cristina Papayannidis,Agnieszka Wierzbowska,Ho Jin Shin,Vadim Doronin,Stefan Deneberg,Su-Peng Yeh,Mehmet Ali Özcan,Steven Knapper,Jorge E. Cortes,Daniel A. Pollyea,Gert J. Ossenkoppele,Sergio Giralt,Hartmut Döhner,Michael Heuser,Liang Xiu,Indrajeet Singh,Fei Huang,Julie S. Larsen,Andrew H. Wei +24 more
TL;DR: Combination therapy showed no improvement in efficacy versus decitabine alone, resulting in the Independent Data Monitoring Committee’s recommendation of early termination of enrollment and discontinuation of talacotuzumab treatment.